📖Editor’s picks: Journal highlights >>> Our Commissioning Editor Jasmine Hagan spotlights her top papers from recent issues, featuring cutting-edge developments that address significant clinical challenges with novel cell therapies, advanced manufacturing techniques, and sustainable biomaterials.

From engineered cardiac patches to cell therapies using mesenchymal and induced pluripotent stem cells >>> hubs.ly/Q04xwBlT0 Our latest eBook explores innovative therapeutic strategies addressing the heart's limited regenerative capacity. Get your free copy!

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04yc-Qx0 > The FDA has approved clinical testing of University of Colorado Anschutz's experimental CAR-T therapy in adults with colorectal cancer and children with solid tumors > Cellectis has pivoted from allogeneic CAR-T therapies to focus on in vivo gene editing therapies for chronic diseases > Glidepath Health has emerged from stealth mode with an AI-driven platform for managing cell and gene therapy logistics

Attending Biotech Week Boston? Read our top picks as we have digested the agenda for you – highlighting key sessions we think shouldn’t be missed! >>> hubs.ly/Q04y7rFq0 #BPI2026 #CellAndGeneTherapy

What if muscle cells hold the key to stopping fibrosis? Cook MyoSite's latest research uncovers the cellular crosstalk that keeps damaged muscle from turning into fat and scar tissue. This discovery could transform treatment for muscular dystrophy and volumetric muscle loss.  Download the White Paper now >>> hubs.ly/Q04xlBwJ0

Read how a novel gene editing method, prime assembly, has demonstrated precise insertion of gene-length DNA fragments into living cells >>> hubs.ly/Q04y2Ckc0

Have you downloaded the whitepaper ‘Cellular crosstalk in muscle tissue regeneration: lessons from FAP differentiation’? Explore research from Cook MyoSite examining the crosstalk between skeletal muscle progenitor cells and fibro-adipogenic progenitor cells that suggests that signals released by healthy myotubes may help keep FAP cells in a less differentiated state.   Learn more here >>>hubs.ly/Q04xlByc0

There’s less than a week until Biotech Week Boston! Have you planned your sessions yet? Check out our top picks to help you plan your time, plus revisit some of our most popular articles to help spark those valuable conversations. Read here: hubs.ly/Q04xDyYx0 @BiotechWkBoston @CellTherapyIC #BiotechWeekBoston

Advancing cardiac regenerative medicine requires human-relevant research models that accurately replicate the heart's complex cellular interactions. Our latest eBook features cutting-edge tools including cardiac spheroids that mimic the beating heart and endothelial cell assays that model angiogenesis. Download now >>> hubs.ly/Q04xwz-Z0

High translational failure rates, oversimplified in vitro systems, and animal models that don't capture the complexity of human tumor biology are driving a fundamental shift in how we evaluate immune cell therapies before they reach patients.  Discover how preclinical models are evolving to bridge this gap >>> hubs.ly/Q04vFxW_0

From selecting the right model system to incorporating relevant microenvironmental factors, multiple considerations shape the quality and interpretability of your data. This infographic outlines six essential considerations to guide your preclinical model design, helping you build more biologically relevant systems that support robust immune cell therapy development >>> hubs.ly/Q04vFQKs0

Find out how a novel gene activation platform, half the size of its CRISPR-based counterpart, could revolutionize the deliverability of gene therapies that target gene expression >>> hubs.ly/Q04x7LYc0

🚨Don't miss our In Focus exploring how preclinical model systems can be used to support the development of immune cell therapies >>> hubs.ly/Q04vFPsP0

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04x6Pkq0 > uniQure submitted regulatory applications for its Huntington’s disease gene therapy in the US and UK > Bristol Myers Squibb announced positive topline results from the registrational Phase II trial assessing its CAR-T therapy for quadruple-class exposed relapsed and refractory multiple myeloma > EpilepsyGTx and Viralgen have entered into a partnership to develop an epilepsy gene therapy

In our latest article, explore in vivo CAR-T programs currently in clinical trials and several that have been acquired by major pharmaceutical companies >>> hubs.ly/Q04x0FjX0

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04wthsD0 >Ocugen announced that it has dosed the first patient in its global Phase III trial for OCU410  > Genprex has partnered with Andelyn Biosciences to advance its diabetes gene therapy program  > Complement Therapeutics has completed its Phase I/II cohort 2 dosing of its gene therapy for geographic atrophy

As immune cell therapies move into more complex solid tumor settings, why is preclinical model design becoming more important?  Three experts answer this question and outline a path forward to build preclinical platforms that better predict clinical outcomes and accelerate the development of effective immune cell therapies.  Read their insights here >>> hubs.ly/Q04vFwjX0

Learn how to design preclinical models that accurately reflect tumor-immune interactions and support the development of immune cell therapies for solid tumors in this infographic >>> hubs.ly/Q04vDSsX0

Discover how researchers are building tumor-immune model systems that better predict clinical outcomes and accelerate immune cell therapy development in our latest In Focus >>> hubs.ly/Q04vFsNV0

The cell and gene therapy sector has seen significant mergers and acquisitions activity over the past year. In this article, we explored billion-dollar acquisitions, including in vivo CAR-T programs, epilepsy cell therapies, and in vivo gene replacement systems – and the year isn't over yet! What mergers and acquisitions do you think are next? Read our latest article here: hubs.ly/Q04vb7KN0